成田キャンパス
皮膚科学教室

皮膚科学教室

教室紹介

業績 2017年

英文論文

  1. Suzuki H, Miyagaki T, Otobe S, Nakajima R, Oka T, Takahashi N, Kabasawa M, Suga H, Yoshizaki A, Asano Y, Sato S, Sugaya M: Increased endocan expression in lesional skin and decreased endocan expression in sera in atopic dermatitis. J Dermatol 44(12):1392-1395 2017
  2. Taniguchi T, Miyagawa T, Tamaki Z, Nakamura K, Yamashita T, Saigusa R, Takahashi T, Toyama T, Ichimura Y, Yoshizaki A, Tada Y, Sugaya M, Kadono T, Sato S, Asano Y: A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis. Arch Dermatol Res 309(10): 833-842 2017
  3. Oka T, Sugaya M, Takahashi N, Nakajima R, Otobe S, Kabasawa M, Suga H, Miyagaki T, Asano Y, Sato S: Increased Interleukin-19 Expression in Cutaneous T-cell Lymphoma and Atopic Dermatitis. Acta derm venereal 97(10): 1172-1177 2017
  4. Miyagawa T, Asano Y, de Mestier Y, Saigusa R, Taniguchi T, Yamashita T, Nakamura K, Hirabayashi M, Miura S, Ichimura Y, Takahashi T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S. Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosis. J Dermatol 44(10): 1168-1171 2017
  5. Saigusa R, Asano Y, Nakamura K, Hirabayashi M, Miura S, Yamashita T, Taniguchi T, Ichimura Y, Takahashi T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S: Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 Deficiency. J Inv Dermatol 137(9): 1850-1859 2017
  6. Takahashi N, Sugaya M, Suga H, Oka T, Kawaguchi M, Miyagaki T, Fujita H, Inozume T, Sato S: Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155. J Inv Dermatol 137(8): 1766-1773 2017
  7. Kamijo H, Sugaya M, Takahashi N, Oka T, Miyagaki T, Asano Y, Sato S: BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines. Arch Dermatol Res 309(6): 491-497 2017
  8. Senda N, Miyagaki T, Oka T, Ito Y, Katayama K, Kamiyama T, Sugaya M, Sato S: Case of mycosis fungoides with gastric and central nervous system involvement. J Dermatol 44(7): e166-e167 2017
  9. Miyagaki T, Sugaya M, Oka T, Takahashi N, Kawaguchi M, Suga H, Fujita H, Yoshizaki A, Asano Y, Sato S: Placental Growth Factor and Vascular Endothelial Growth Factor Together Regulate Tumour Progression via Increased Vasculature in Cutaneous T-cell Lymphoma. Acta derm venereal 97(5): 586-592 2017
  10. Oka T, Sugaya M, Takahashi N, Takahashi T, Shibata S, Miyagaki T, Asano Y, Sato S: CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells. J Immunol 198(10): 3897-3908 2017
  11. Takahashi N, Sugaya M, Oka T, Miyagaki T, Sato S: Alopecia areata, thyroiditis and vitiligo vulgaris in a Japanese patient with smoldering type adult T-cell leukemia/lymphoma. J Dermatol 44(4) e79-e80 2017

和文論文

  1. 菅谷誠. リンパ浮腫に対するシロスタゾールの効果 リンパ学 40(1): 48-52, 2017.
  2. 菅谷誠. アトピー性皮膚炎治療の新展開 喘息・アレルギー 30(1): 66-69, 2017.
  3. 菅谷誠. 皮膚リンパ腫は難しくない 皮膚悪性リンパ腫が難しい理由を病態から考える 日本臨床皮膚科医会雑誌 34(6): 716-720, 2017.
  4. 菅谷誠. 皮膚T細胞リンパ腫治療の進展 皮膚T細胞リンパ腫 最近の治療オーバービュー Skin Cancer 32(2) 159-161, 2017.
  5. 菅谷誠. リンフォーマの診断と治療 皮膚病診療39(9) 918-923, 2017.
  6. 菅谷誠. 免疫表現型に基づいたリンパ系腫瘍の理解】 皮膚T細胞リンパ腫の免疫表現型による分類と予後 血液内科 74(6): 808-812, 2017.
  7. 菅谷誠. 【皮膚科治療薬処方ガイド-年齢・病態に応じた薬の使い方-】 インターフェロンγ-1a、ボリノスタットDerma. 255: 179-182, 2017.
  8. 菅谷誠. 【最近のトピックス2017 Clinical Dermatology 2017】皮膚疾患治療のポイント 皮膚悪性リンパ腫の新規薬物療法 臨床皮膚科71(5): 121-124, 2017.